Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.67 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.37 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154108 | 0.87 | EGLN1 (0.54) | EGLN1CACNA1HCACNA1BCACNA1C | |
| SCHEMBL17137650 | 0.79 | EGLN1 (0.69) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL17137651 | 0.79 | EGLN1 (0.69) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL17137737 | 0.79 | EGLN1 (0.69) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL3427756 | 0.77 | EGLN1 (0.42) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL12496292 | 0.75 | CACNA1H (0.51) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844774 | 0.74 | CACNA1B (0.52) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15852939 | 0.73 | CACNA1H (0.51) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844303 | 0.72 | CACNA1H (0.68) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844569 | 0.72 | CACNA1B (0.68) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | claimed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | EGLN1 5/4885CACNA1H 4630/4885CACNA1B 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.